In tablet manufacturing for companion-animal dermatological infections, the crystalline monohydrate form of cephalexin is rarely direct-compressed at commercial scale because its poor compactibility, low bulk density, and tendency to segregate from coarse carrier particles produce unacceptable content uniformity drift on rotary presses. Wet granulation in a top-drive high-shear mixer with impeller tip speed from 3 m/s to 8 m/s and chopper speed from 1400 rpm to 2800 rpm is used with povidone K30 at 2.5–5.0% w/w as binder; granulation endpoint is controlled not by fixed time but by differential power draw reaching 15–25% above the dry-mix baseline. The wet mass is milled through a 2.0 mm conical screen and dried in a fluid-bed dryer with inlet air at 55–65°C until loss on drying by USP <731> is ≤2.0% w/w. Dried granules are blended with microcrystalline cellulose 30–45% w/w, croscarmellose sodium 2–4% w/w, and magnesium stearate 0.5–0.75% w/w; final lubrication time is held to 3–5 min at 10–20 rpm to avoid overlubrication. Compression on a 16–20 station rotary tablet press at 8–15 kN produces 250 mg and 500 mg tablets with hardness 60–100 N, friability ≤0.8% per USP <1216>, disintegration ≤30 min per USP <701>, and dissolution Q 80% at 30 min in 900 mL water at 50 rpm using USP <711> apparatus 2. Compliance is maintained under Regulation (EU) 2019/6 for veterinary medicinal products and the relevant monograph for cephalexin oral solids, with batch records documenting granule particle size distribution D10/D50/D90 limits and compression force main effects. Terminal dosage form: immediate-release film-coated tablets for oral administration; the coating system is typically hydroxypropyl methylcellulose with polyethylene glycol at 2–3% w/w total solids applied in a side-vented pan at exhaust air 45–55°C.

Why Do Injectable Suspensions Require Dv90 Control Below 15 µm for 25-Gauge Needle Passage?

Parenteral cephalexin monohydrate suspensions present a dual challenge: the API’s temperature-dependent solubility and its needle-clogging risk if particle size distribution shifts during terminal sterilization. Aseptic processing rather than moist-heat sterilisation at 121°C is selected because cephalexin undergoes β-lactam hydrolysis above 70°C at neutral pH; published degradation kinetics in phosphate buffers show maximum stability at pH 3.5–5.0, with hydrolysis accelerating above pH 6.0. For a 200 mg/mL injection, micronisation to Dv90 ≤15 µm via air-jet milling with nitrogen at 6–8 bar and classifier speed 8000–12000 rpm is followed by high-pressure homogenisation at 600–1000 bar to reduce Dv99 below 35 µm. The aqueous vehicle contains polysorbate 80 at 0.1–0.3% w/v, sodium chloride 0.9% w/v for isotonicity, methyl parahydroxybenzoate 0.18% w/v, and propyl parahydroxybenzoate 0.02% w/v. Sodium carboxymethylcellulose at 0.2–0.5% w/v provides suspension viscosity of 20–50 mPa·s at 25°C; syringeability through 21–25 G needles is measured by texture analyser with a 50 N load cell at 1 mL/s, and the acceptance criterion is no occlusion and force ≤15 N. Sterility is tested per USP <71>, bacterial endotoxin limit ≤0.20 EU/mg per USP <85>, and zeta potential is maintained between -25 mV and -40 mV to reduce caking. Incompatibility arises with alkaline buffers and with divalent cation salts; calcium chloride or magnesium sulfate added for tonicity adjustment can displace surface charge and lead to flocculation. Terminal dosage form: sterile injectable suspension for intramuscular or subcutaneous use in cattle, swine, or companion species, filled in amber vials under nitrogen headspace to limit oxidative discoloration.

Batch-to-batch variance on industrial filling lines is most often traced to uncontrolled particle growth during milling because residual moisture above 2.0% w/w promotes amorphous bridging in the jet mill. The milling chamber is therefore pre-conditioned at relative humidity 40–50% and the API is vacuum-dried before micronisation. In-process tests include laser diffraction particle size, scanning electron microscopy for needle-shaped fragments, and viscosity after 72 h of storage at 25°C to confirm fully hydrated suspending agent network. Published data for cephalexin injection-specific degradation under terminal sterilisation is limited, so the aseptic route is retained as default.

Capsule filling operations for feline urinary tract protocols require tight fill weight variation control because approved dosing is commonly 15–25 mg/kg body weight twice daily, translating to capsule strengths of 125 mg and 250 mg. The API is pre-blended with lactose monohydrate 60–75% w/w and sodium starch glycolate 2–5% w/w, then slugged or roller-compacted to improve flow for tamping-pin capsule fillers. Fill weight variation must meet USP <905> acceptance value ≤15 for 10 capsules; content uniformity acceptance value is ≤15.0. Moisture content in the finished capsule shell and granular material is held below 4.0% w/w by Karl Fischer method USP <921> because cephalexin monohydrate can release bound water and cause shell embrittlement below 40% RH or cross-linking above 60% RH. Hard gelatin capsule size 2 for 125 mg and size 0 for 250 mg are typical. Dissolution in 0.1 N hydrochloric acid is performed per USP <711> apparatus 1 at 100 rpm, Q 80% at 30 min. Terminal dosage form: hard capsules for oral administration.

On semi-automatic and fully automatic capsule machines, powder bridging in hoppers is a repeat failure mode when the roller-compacted granules exceed 1.0 mm or when lubricant is added too early. The process sequence is therefore: blend API with filler and disintegrant for 15–20 min in a V-blender at 20 rpm, compact at roll pressure 2–6 MPa, mill through 0.8–1.25 mm screen, lubricate with magnesium stearate 0.5–1.0% w/w for 2–3 min, and fill immediately. Batch uniformity is monitored by in-process weight checks every 15 min with a tolerance of ±3% from target fill weight. Capsules are packaged with desiccant when storage zone humidity exceeds 60% RH.

Because water-soluble powder lines are frequently reconstituted with untreated borehole water, formulations are designed around total hardness values above 300 mg/L as CaCO₃, where calcium and magnesium ions compete with cephalexin for carboxylate hydration and can promote precipitation in stock solutions. Citric acid anhydrous at 10–25% w/w adjusts reconstituted solution pH to 3.5–4.5; lactose monohydrate or maltodextrin serves as the carrier. The API is processed by 1:10 geometric dilution series; final bulk potency is typically 5.0–10.0% w/w cephalexin. For granules, fluidised-bed top-spray granulation with povidone K30 3–5% w/w at inlet air 60–70°C and spray rate 50–100 g/min produces particle size 200–600 µm, bulk density 0.55–0.70 g/mL, and moisture ≤2.5% w/w. A 1 g/L stock solution in potable water is administered over 24 h; no stock solution is held beyond 24 h at ambient temperature because hydrolysis accelerates above pH 6.0. Assay by USP <621> HPLC requires resolution between cephalexin and cephalexin-related degradation peaks. Terminal dosage form: water-soluble powder and granules for drinking water administration in poultry or swine.

Field failure modes in poultry operations include nozzle clogging in proportioning medicators when the granule fraction below 100 µm exceeds 15% w/w; dust collectors reduce yield and require containment. Sieve analysis is therefore performed on every batch, and oversized material above 800 µm is milled back through a screen mill. The finished pack is double polyethylene-lined to keep moisture uptake below 0.5% w/w over 24 months in climate zone II conditions.

When Cephalexin Premix Must Meet Carryover Limits Below 1% of Therapeutic Dose

Feed premix production for swine respiratory bacterial infections imposes homogeneity and carryover constraints that are not present in pharmaceutical granulation. The active concentration in the premix is commonly 5.0–10.0 g cephalexin per 100 g; this is diluted into complete feed at 0.5–2.0 kg per tonne depending on species and regulatory status. A ribbon blender with working volume 70–80% and mixing time 15–20 min at 15–25 rpm is used after 1:10 stepwise pre-blends; coefficient of variation for 10 samples at final mix must be ≤5.0% when assayed by HPLC per USP <621>. The carrier is selected to match particle size distribution of the complete feed: ground corn cob 200–500 µm or lactose 100–300 µm. Electrostatic adhesion to stainless steel surfaces is reduced by maintaining relative humidity 45–60% in the mixing suite. Cleaning validation uses a worst-case swab limit calculated from NOEL; if the next product is non-antibiotic, carryover must be below 1% of the lowest therapeutic dose. Terminal dosage form: medicated feed premix for oral administration via complete feed.

Batch-to-batch variance in premix homogeneity is amplified when the API is added directly to the blender without pre-blending; this produces stratified pockets that survive final feed mixing. A validated stepwise mixing protocol with three to five pre-mix stages and pause intervals of 5 min at each stage is used. The premix is packed in 20 kg paper sacks with polyethylene liner, and storage is at 25°C with humidity below 65% RH. Segregation during bulk transport is minimized by limiting particle size differential between API and carrier to 3:1 maximum. Terminal release includes HPLC identity, assay, and loss on drying per USP <731>.

Reconstituted Oral Suspension Viscosity, Preservation, and Beyond-Use Dating

Dry powder for oral suspension intended for neonatal calves or foals is blended with sucrose 55–70% w/w, xanthan gum 0.2–0.4% w/w, and sodium carboxymethylcellulose 0.1–0.3% w/w to achieve a yield stress of 0.5–2.0 Pa and apparent viscosity 100–300 mPa·s at 25°C after reconstitution to 125 mg/5 mL. Preservation uses sodium benzoate 0.1–0.2% w/v and potassium sorbate 0.1–0.2% w/v; microbiological effectiveness testing per USP <51> must show no growth after challenge with specified organisms. The reconstituted suspension is stored at 2–8°C for 14 days; beyond-use dating is supported by stability studies showing ≤10% potency loss and no visible caking. Buffering to pH 4.0–4.5 with citrate buffer 0.05 M reduces β-lactam hydrolysis; addition of alkaline flavours or sweeteners that raise pH above 6.0 is incompatible. Terminal dosage form: oral suspension after reconstitution.

In production, dry blending followed by sifting through 500 µm mesh is used instead of wet granulation to avoid heat-induced degradation of the suspending agent. The powder is filled into amber HDPE bottles with desiccant and headspace oxygen below 5%. Reconstitution with tap water to the fill line is expected to produce a homogeneous suspension with sedimentation volume ratio not less than 0.9 at 2 h. Batch-to-batch viscosity variation is controlled by standardising the xanthan gum dispersion time and hydration temperature at 20–25°C; hydration above 60°C causes irreversible viscosity loss.

Intramammary paste manufacturing for lactating dairy cattle requires anhydrous oleaginous vehicles because the presence of free water accelerates cephalexin hydrolysis and supports microbial growth in single-dose syringes. Cephalexin monohydrate is dispersed at 10–20% w/w in a vehicle of white petrolatum and aluminium monostearate 2–4% w/w, prepared by heating to 155–165°C for sterilisation, cooling to 40–45°C, and mixing under vacuum 0.8 bar to remove entrapped air. Viscosity at 25°C at shear rate 10 s⁻¹ is 10,000–30,000 mPa·s; the product must pass syringeability through a 13 mm intramammary cannula with extrusion force below 40 N at 25°C. Sterility per Ph. Eur. 2.6.1, bacterial endotoxin limit ≤0.5 EU/mL. Avoid incorporation of aqueous buffer into anhydrous oleaginous base because free water reduces chemical stability and supports microbial growth. Published data for cephalexin-specific paste rheology is limited; process validation therefore relies on semi-solid processing parameters and batch release rheograms rather than historical cephalexin paste data. Terminal dosage form: sterile intramammary paste.